Skip to main content

Advertisement

SpringerLink
Log in

Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the effects of multidisciplinary and comprehensive Chinese medicine (CM) treatments on progression-free survival (PFS) and median survival time (MST) in patients with advanced non-small cell lung cancer (NSCLC) and identify factors that influence progression and prognosis.

Methods

Clinical data of 855 patients with advanced NSCLC who received multidisciplinary and comprehensive CM treatments at Longhua Hospital from January 2009 to December 2018 were retrospectively analyzed. Univariate analysis was performed by the Kaplan-Meier method and log-rank sequential inspection. Multivariate analysis of significant variables from the univariate analysis was performed with Cox regression modeling. Key factors correlated to progression and prognosis were screened out, and a Cox proportional hazard model was established to calculate the prognostic index.

Results

The PFS and MST of 855 advanced NSCLC patients were 9.0 and 26.0 months, respectively. The 1-, 2-, 3-, and 5-year survival rates were 79.2%, 54%, 36.2%, and 17.1%, respectively. Gender, pathologic type, and clinical stage were independent prognostic risk factors; surgical history, radiotherapy, treatment course of Chinese patent medicine, intravenous drip of Chinese herbal preparation, duration of oral administration of Chinese herbal decoction (CHD), and intervention measures were independent prognostic protective factors. Gender was an independent risk factor for progression, while operation history and oral CHD administration duration were independent protective factors (all P<0.05). Women with stage IIIb–IIIc lung adenocarcinoma had the best outcomes.

Conclusions

Female patients have lower progression risk and better prognoses than male patients, younger patients have higher progression risk but better long-term prognoses than the elderlys, and patients with lower performance status scores are at lower risk for progression and have better prognoses. Comprehensive CM treatments could significantly reduce progression risk, improve prognosis, and prolong survival time for patients with advanced NSCLC. This treatment mode offers additional advantages over supportive care alone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zheng RS, Sun KX, Zhang SW, Zeng HM, Zou XN, Chen R, et al. Report of cancer epidemiology in China, 2015. Chin J Oncol (Chin) 2019;41:19–28.

    CAS  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA-Cancer J Clin 2019;69:7–34.

    Article  Google Scholar 

  3. Chen WQ, Zheng RS, Baade PD, Zhang S, Zeng H, Bray F, et al. Caner statistics in China, 2015. CA Cancer J Clin 2016;66:115–132.

    Article  Google Scholar 

  4. Chinese Anticancer Association. New criteria of diagnosis and treatment for common malignant tumors. Beijing: Beijing Union Medical University Press;1999:773–781.

    Google Scholar 

  5. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage Groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016;11:39–51.

    Article  Google Scholar 

  6. Zheng XY, ed. Guidelines of traditional Chinese medicine new drugs for the clinical research. Beijing: China Medical Science and Technology Press; 2002:217–218.

    Google Scholar 

  7. Shanghai Municipal Health Bureau. Shanghai Routine of Diagnosis and Treatment of TCM Disease and Syndrome. Shanghai: Shanghai University of Tradition Chinese Medicine Press; 2003:128.

    Google Scholar 

  8. Sun JL, Li CJ, Li HG, Liu LS, Tian JH. An introduction of LIU Jia-xiang’s academic thought about ‘strengthening vital qi to treat cancer’. J Tradit Chin Med (Chin) 2006;47:814–816.

    Google Scholar 

  9. Zhou CC. A revision of NCCN guideline for non-small cell lung cancer 2008. Tumor (Chin) 2008;28:183–186.

    Google Scholar 

  10. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:69–90.

    Article  Google Scholar 

  11. Ahmad U, Ruschel M, Detterbeck FC. Lung cancer: facts, figures and reflections on spending. J Cancer Ther 2012;3:123–126.

    Article  Google Scholar 

  12. Li HG. Professor LIU Jia-xiang’s treatment experience of lung cancer is based on scientific theory system about ‘strengthening vital qi to treat cancer’. J Sichuan Tradit Chin Med (Chin) 2005;7:5–6.

    Google Scholar 

  13. Tian JH, Luo B, Liu JX. Biological basis of hidden toxicity due to vital qi deficiency in lung cancer: I. Discussion on vital qi deficiency in lung cancer from immunologic derangement. Shanghai J Tradit Chin Med (Chin) 2018;52:1–4.

    Google Scholar 

  14. Tian JH, Luo B. Biological basis of hidden toxicity due to vital qi deficiency in lung cancer: II. Discussion on hidden toxicity in lung cancer from occult tumor cells. Shanghai J Tradit Chin Med (Chin) 2018;52:6–10.

    Google Scholar 

  15. Yao JL, Gong YB, Xu L. Role of Chinese medicine therapy in postoperative rehabilitation of lung cancer survivors. Med Recapit (Chin) 2017;23:4721–4725.

    Google Scholar 

  16. Guo XW, Hu ND, Sun GZ, Li M, Zhang PT. Shenyi Capsule plus chemotherapy versus chemotherapy for non-small cell lung cancer: a systematic review of overlapping meta-analyses. Chin J Integr Med 2018;24:227–231.

    Article  CAS  Google Scholar 

  17. Chen YZ, Li ZD, Zhou N, Sun H, Li PP. Longer overall survival in a patient with advanced NSCLC treated with Chinese medicine and chemotherapy. Chin J Integr Med 2012;18:626–628.

    Article  Google Scholar 

  18. Yang XB, Chai XS, Wu WY, Long SQ, Deng H, Pan ZQ, et al. Gefitinib plus Fuzheng Kang’ai Formula in patients with advanced non-small cell lung cancer with epidermal growth factor receptor mutation: a randomized controlled trial. Chin J Integr Med 2018;24:734–740.

    Article  CAS  Google Scholar 

  19. He XR, Han SY, Li PP. Recent highlights of Chinese medicine for advanced lung cancer. Chin J Integr Med 2017;23:323–330.

    Article  Google Scholar 

  20. Xu WJ, Li HG, Pu YQ, Zhao LH, Tian JH, Zhu LH, et al. Retrospectively study of traditional Chinese medicine in the treatment of advanced non-small cell lung cancer. Acad J Shanghai Univ Tradit Chin Med (Chin) 2017;3105:27–31.

    Google Scholar 

  21. Chen YZ, Feng XB, Li ZD, Zheng WX, Sun H, Li PP. Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and Western medicine. Chin J Integr Med 2014;20:179–183.

    Article  Google Scholar 

  22. Xu HZ, Zhang X, Sun JL. Multi-factor analysis of EGFR-TKIs combined with TCM in the treatment of NSCLC. Li Shi-zhen Med Mater Med Res (Chin) 2017;28:2156–2158.

    Google Scholar 

  23. Xin XL, Jiang Yi, Shen LP, Liu LS. Survival analysis of 600 elderly patients with non-small cell lung cancer treated with traditional Chinese medicine. J Tradit Chin Med (Chin) 2019;60:31–35.

    Google Scholar 

  24. Gregory AM, Sarah T, Christopher GA, Giuseppe G, Sherman B, Julie RB, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol 2015;33:3488–515.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Third Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China

    Xian-ge Huang, Li-hua Zhu, Lei Zhou, Wei-jie Xu, Yi-lin Yao, Zhi-yi Zhou & He-gen Li

Authors
  1. Xian-ge Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li-hua Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lei Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei-jie Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi-lin Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zhi-yi Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. He-gen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors have contributions to coin the idea of this paper. They all read and approved the final manuscript. Huang XG drew up the first draft, designed and conducted the research plan; Zhu LH designed the research plan; Zhou L and Yao YL conducted the research plan; Xu WJ and Zhou ZY followed up the patients. Li HG supervised and had the primary responsibility for this paper.

Corresponding author

Correspondence to He-gen Li.

Additional information

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Supported by National Thirteenth Five-Year Science and Technology Major Special Project for New Drug Innovation and Development (No. 2017ZX09304001); Shanghai Three-Year Action Plan for Further Accelerating the Development of TCM [No. ZY(2018-2020)-CCCX-1016]; Shanghai Emerging Interdisciplinary Funding Program of TCM; Construction of the most Important Clinical Medical Center and Key Disciplines in Shanghai (No. 2017ZZ01010); Pudong New Area Health Select Committee Health and Family Planning Scientific Research Project Plan (No. PW2019E-1); Shanghai Key Clinical Specialty Project (No. shslczdzk03701)

Electronic supplementary material

11655_2020_3428_MOESM1_ESM.pdf

Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Xg., Zhu, Lh., Zhou, L. et al. Multidisciplinary and Comprehensive Chinese Medicine for Advanced Non-Small Cell Lung Cancer Patients: A Retrospective Study of 855 Cases. Chin. J. Integr. Med. 27, 490–495 (2021). https://doi.org/10.1007/s11655-020-3428-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-020-3428-5

Keywords

Search

Navigation